You are here: Industry Insights > ESMO

News List

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024 PharmaSources
September 14, 2024
Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the European Society for Medical Oncology (ESMO) Congress 2024.
ESMO drives EU-level action to tackle shortages of essential medicines europeanpharmaceuticalreview
April 12, 2019
Shortages of inexpensive, essential medicines: calling for tangible political commitments in the EU…
ESMO drives EU-level action to tackle shortages of essential medicines europeanpharmaceuticalreview
April 12, 2019
Shortages of inexpensive, essential medicines: calling for tangible political commitments in the EU…
Jonas Bergh receives first ESMO Breast Cancer Award biospectrumasia
April 03, 2019
The ESMO Breast Cancer Award acknowledges distinguished experts who have devoted a major part of their career and made……
Roche's Alecensa topples Pfizer's Xalkori in Asian patients with ALK+ advanced lung cancer pharmafile
November 01, 2018
Following up on the reveal of data concerning its immunotherapy Tecentriq in combination with chemotherapy in the treatment of non-small cell lung cancer, Roche unveiled a second wave of findings at the European ...
Balixafortide combination with eribulin in metastatic breast cancer data presented at ESMO 2018 show consistent positive trend for all efficacy endpoints, including overall survival firstwordpharma
October 25, 2018
Balixafortide combination with eribulin in metastatic breast cancer data presented at ESMO 2018 show consistent positive trend for all efficacy endpoints, including overall survival
ESMO celebrates successful completion of 3RD ESMO ASIA CONGRESS in Singapore biospectrumasia
November 23, 2017
The momentum continues as experts around the world gather to advance cancer care.
ESMO: Merck's Keytruda extends survival edge on its bladder cancer rivals fiercepharma
September 11, 2017
MADRID, Spain—Right now, Merck’s Keytruda is the only PD-1/PD-L1 med with data to show it can improve overall survival in the second-line bladder cancer setting.
ESMO welcomes the adoption of the 2017 WHO Cancer Resolution europeanpharmaceuticalreview
June 05, 2017
ESMO, the leading European professional organisation for medical oncology, welcomes the adoption of the Resolution on Cancer prevention and control in the context of an integrated approach during the 70th World Health Assembly (WHA), May 22 to 31 in Genev